Filed with ASX · · 5 pages · English
Clarity Pharmaceuticals Ltd. has announced that its registrational Phase III CLARIFY trial has successfully dosed the planned target number of participants in the study. Topline data from the trial is expected to be released in the first half of the following year, which will support an application for FDA approval. This milestone is seen as a significant achievement for the company as it progresses towards trial completion and potential product launch.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
A S X A N N O U N C E M E N T 27 October 2026 Registrational Phase III CLARIFY trial: Target number of participants achieved Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that...
Clarity Pharmaceuticals Ltd. on 6ix
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals